Lv41
698 积分 2025-07-10 加入
Discovery of DN1679 as a Potent, Orally Bioavailable, and Highly Selective CDK12/13 Dual Degrader for the Treatment of Triple-Negative Breast Cancer
7天前
已完结
Medicinal Chemistry of Pyrazolopyrimidine Scaffolds Substituted with Different Heterocyclic Nuclei
16天前
已完结
An Overview of CDK Enzyme Inhibitors in Cancer Therapy
16天前
已完结
Targeting CDK2 and other novel cell cycle targets for breast cancer therapy
16天前
已完结
Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer
16天前
已完结
Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy
16天前
已完结
DEVELOPMENT OF E3 LIGANDS TO ENABLE NEXT-GENERATION DEGRADERS
17天前
已完结
Implications of frequent hitter E3 ligases in targeted protein degradation screens
22天前
已完结
Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib
27天前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
28天前
已完结
皖公网安备34019202002308
